Dr. David Chen
MD, PhD, FAAP — Chief of Pediatric Oncology & Cellular Therapeutics
Pediatric Hematology-Oncology
Biography & Clinical Philosophy
Dr. David Chen is a physician-scientist specializing in targeted immunotherapies and genomic medicine for pediatric leukemias. He holds a combined MD/PhD from Stanford University and completed his fellowship at St. Jude Children’s Research Hospital.
Education & Medical Training
Degrees & Medical Education
- MD & PhD in Immunology — Stanford University School of Medicine
- BS in Biochemistry — UC Berkeley
Residencies & Fellowships
- Pediatric Residency — Lucile Packard Children’s Hospital Stanford
- Fellowship in Pediatric Hematology-Oncology — St. Jude Children’s Research Hospital
Clinical Research & Academic Inquiries
CAR-T cell therapy protocols in relapsed pediatric B-ALL and targeted cellular therapeutics.
Sacred Heart Journal Publications (1)
Browse In RepositoryTargeted Anti-CD19 CAR T-Cell Therapy for Relapsed Pediatric Acute Lymphoblastic Leukemia: Managing Cytokine Release and Inpatient Protocols
Chimeric antigen receptor (CAR) T-cell therapy represents a transformative treatment for children with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL).\n\nHere we review institutional protocols implemented at Sacred Heart across 64 pediatric infusions, evaluating early intervention with tocilizumab and dexamethasone. Implementation of automated telemetry monitoring and resident-driven grading protocols reduced ICU escalation for severe Grade 3/4 CRS from 24% to 9.4% while maintaining 12-month minimal residual disease-negative remission rates of 87.5%.
Get in Touch
For clinical inquiries, second opinions, and medical evaluations with Dr. David Chen.